Ilyang Pharmaceutical Co.,Ltd (KRX:007575)

South Korea · Delayed Price · Currency is KRW

6,800.00

-20.00 (-0.29%)

Nov 4, 2026, 3:30 PM KST

Market Cap	122.07B -47.8%
Revenue (ttm)	277.96B +0.6%
Net Income	16.46B +69.0%
EPS	946.42 +66.6%
Shares Out	n/a
PE Ratio	7.18
Forward PE	n/a
Dividend	180.00 (2.65%)
Ex-Dividend Date	Dec 29, 2025

Volume	25
Open	6,810.00
Previous Close	6,820.00
Day's Range	6,650.00 - 6,810.00
52-Week Range	6,350.00 - 15,260.00
Beta	0.37
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About KRX:007575

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and be... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1946

Employees 660

Stock Exchange Korea Stock Exchange

Ticker Symbol 007575

Financial Performance

In 2025, KRX:007575's revenue was 272.42 billion, an increase of 1.39% compared to the previous year's 268.68 billion. Earnings were 6.73 billion, a decrease of -25.52%.

Financial Statements